Cardiology VIVA :
50 CT ANGIOGRAPHY & CARDIAC MRI (CMR) MASTER LIST
Diagnosis: Aortic Dissection.
Pathognomonic Sign: Intimal flap separating the aorta into a true and false lumen.
Clinical Risk: Aortic rupture, malperfusion syndrome, cardiac tamponade (Type A).
Management: Type A requires emergent surgery; Type B is managed medically (BP control) unless complicated.
Cross-Examination (5 Q&A):
Q: How do you identify the true lumen on CT? A: It is usually smaller, strongly enhanced, and may have outer wall calcification.
Q: What is the "beak sign"? A: Acute angle formed by the false lumen at the edge of the intimal flap.
Q: What is the "cobweb sign"? A: Slender linear structures (residual media) seen exclusively in the false lumen.
Q: Stanford Type A vs B? A: Type A involves the ascending aorta; Type B is distal to the left subclavian.
Q: What is a penetrating aortic ulcer (PAU)? A: Atherosclerotic plaque eroding into the aortic media, a dissection precursor.
2. Coronary Artery Disease (Calcium Scoring)
Diagnosis: Coronary Artery Calcification.
Pathognomonic Sign: High-density (hyperattenuating) calcified plaques along the coronary vessels on a non-contrast CT.
Clinical Risk: Flow-limiting stenosis and future myocardial infarction.
Management: Calculate Agatston score to guide statin therapy intensity.
Cross-Examination (5 Q&A):
Q: What is the threshold for a "severe" Agatston score? A: A score greater than 400.
Q: Does a score of 0 rule out CAD? A: It rules out calcified plaques, but non-calcified (soft) plaques may still be present.
Q: What HU (Hounsfield Unit) defines calcium on this scan? A: Density of 130 HU or greater.
Q: What limits the accuracy of calcium scoring? A: High heart rates and motion artifacts.
Q: At what score is stress testing typically indicated? A: Usually above 400, especially in symptomatic patients.
3. Coronary Artery Stenosis (CCTA)
Diagnosis: Coronary Artery Stenosis.
Pathognomonic Sign: Focal contrast filling defect or luminal narrowing within the coronary artery on contrast-enhanced CT.
Clinical Risk: Demand ischemia and acute coronary syndrome.
Management: FFR-CT analysis or invasive coronary angiography if severe.
Cross-Examination (5 Q&A):
Q: What is the main artifact that mimics stenosis? A: Blooming artifact from dense calcium.
Q: Which coronary segment is hardest to image? A: The mid-RCA (due to maximum cardiac motion).
Q: What is the role of Beta-blockers before the scan? A: To lower the HR below 60 bpm for optimal image quality.
Q: What is FFR-CT? A: Computational fluid dynamics applied to CT to estimate the FFR without a wire.
Q: Is CCTA better for ruling in or ruling out CAD? A: Excellent NPV; it is best for ruling out CAD.
4. Coronary Artery Anomalies
Diagnosis: Anomalous Coronary Artery.
Pathognomonic Sign: Abnormal takeoff of a coronary vessel from the opposite sinus of Valsalva.
Clinical Risk: Sudden Cardiac Death (SCD), especially during exercise.
Management: Surgical unroofing or bypass for malignant courses.
Cross-Examination (5 Q&A):
Q: What defines a "malignant" course? A: An interarterial course (between the aorta and pulmonary artery).
Q: Why does the interarterial course cause ischemia? A: Slit-like ostium & compression by great vessels during exertion.
Q: What is the most common benign anomaly? A: Separate ostia of the LAD and LCx in the left coronary sinus.
Q: What is ALCAPA? A: Anomalous LCA from the Pulmonary Artery (Bland-White-Garland syndrome).
Q: Best imaging modality for anomalies? A: CCTA, due to its excellent 3D spatial resolution.
5. Pulmonary Embolism
Diagnosis: Acute Pulmonary Embolism.
Pathognomonic Sign: Central dark filling defect within the contrast-opacified pulmonary artery.
Clinical Risk: Right heart failure, obstructive shock.
Management: Systemic anticoagulation; assess for thrombolysis if hemodynamically unstable.
Cross-Examination (5 Q&A):
Q: What is the "polo mint" sign? A: A central filling defect surrounded by contrast on an axial slice.
Q: What CT sign indicates right heart strain? A: RV/LV diameter ratio greater than 1.0.
Q: What is the "railway track" sign? A: Longitudinal view of a floating thrombus in the vessel.
Q: How do you differentiate acute from chronic PE? A: Acute is central and expands the vessel; chronic is eccentric and calcified.
Q: What is a saddle embolus? A: A massive thrombus straddling the bifurcation of the main pulmonary trunk.
6. Takayasu Arteritis
Diagnosis: Takayasu Arteritis.
Pathognomonic Sign: Circumferential, smooth thickening of the aortic wall and its primary branches.
Clinical Risk: Aortic occlusion, severe hypertension (if renal arteries involved).
Management: Systemic corticosteroids and immunosuppression.
Cross-Examination (5 Q&A):
Q: What is the "macaroni sign"? A: Diffuse, long-segment circumferential wall thickening seen on ultrasound/CT.
Q: Who is the classic demographic? A: Young females (under 40) of Asian descent.
Q: Does it cause stenosis or aneurysms? A: Both, but stenosis/occlusion is more common.
Q: Differentiate from Giant Cell Arteritis? A: GCA typically affects older patients (over 50) and cranial vessels.
Q: What is the role of FDG-PET? A: To assess active vessel wall inflammation versus chronic fibrosis.
7. Cardiac Sarcoidosis (CMR)
Diagnosis: Cardiac Sarcoidosis.
Pathognomonic Sign: Patchy, multifocal Late Gadolinium Enhancement (LGE), typically mid-wall or epicardial, not conforming to a coronary territory.
Clinical Risk: Ventricular Tachycardia and complete heart block.
Management: ICD placement and immunosuppressive therapy.
Cross-Examination (5 Q&A):
Q: Which regions of the heart are most commonly affected? A: Basal septum and lateral LV wall.
Q: What happens to T2 mapping values? A: T2 is elevated in areas of active granulomatous inflammation (edema).
Q: How does the LGE pattern differ from ischemic heart disease? A: Ischemic LGE always involves the subendocardium.
Q: Why use FDG-PET alongside CMR? A: CMR shows scar (LGE), PET shows active inflammation (FDG uptake).
Q: What dietary prep is needed for Cardiac PET? A: High-fat, low-carb diet to suppress normal myocardial glucose uptake.
8. Hypertrophic Cardiomyopathy (CMR)
Diagnosis: HCM.
Pathognomonic Sign: Asymmetric septal hypertrophy with focal LGE at the right ventricular insertion points.
Clinical Risk: Sudden Cardiac Death, LVOT obstruction.
Management: Beta-blockers, septal reduction therapy, and ICD risk stratification.
Cross-Examination (5 Q&A):
Q: Why does LGE occur at the insertion points? A: Increased mechanical stress and myocardial disarray at the hinge points.
Q: Does the extent of LGE matter? A: Yes, LGE greater than 15 percent of LV mass is an independent risk factor for SCD.
Q: What is SAM? A: Systolic Anterior Motion of the mitral valve, visible on cine CMR.
Q: What is apical HCM? A: Hypertrophy localized to the apex, showing a "spade-like" cavity in diastole.
Q: Differentiate from athlete's heart? A: Athlete's heart rarely exceeds 15mm thickness and lacks LGE.
9. Cardiac Amyloidosis (CMR)
Diagnosis: Cardiac Amyloidosis.
Pathognomonic Sign: Global, diffuse subendocardial LGE with abnormal myocardial nulling kinetics.
Clinical Risk: Restrictive heart failure, arrhythmias.
Management: Bone scintigraphy (PYP scan) to type it, then targeted therapy (e.g., Tafamidis for ATTR).
Cross-Examination (5 Q&A):
Q: What is meant by "abnormal nulling"? A: The myocardium and blood pool null at the exact same time (or blood nulls first).
Q: What is the "zebra stripe" pattern? A: Alternating layers of subendocardial LGE.
Q: How is T1 mapping used here? A: Extracellular Volume (ECV) is massively expanded (often >40%).
Q: Which is more common, AL or ATTR? A: ATTR is increasingly recognized as a major cause of HFpEF in the elderly.
Q: Why avoid Gadolinium in severe cases? A: Risk of Nephrogenic Systemic Fibrosis if the patient has severe renal failure (often seen in AL).
10. Myocardial Infarction (CMR)
Diagnosis: Prior Myocardial Infarction.
Pathognomonic Sign: LGE extending from the subendocardium toward the epicardium in a specific coronary territory.
Clinical Risk: Heart failure, regional wall motion abnormalities.
Management: Guideline-directed medical therapy for heart failure.
Cross-Examination (5 Q&A):
Q: What confirms the diagnosis of ischemic etiology? A: The scar MUST involve the subendocardium.
Q: What does microvascular obstruction (MVO) look like? A: A dark, unenhanced core within a bright area of LGE.
Q: Does MVO have a good or bad prognosis? A: Bad; it indicates no-reflow and poor remodeling.
Q: How do you assess viability? A: Segments with less than 50% transmural thickness of LGE are considered viable.
Q: What is the rule of thumb for revascularization benefit? A: LGE less than 50% = likely to recover function.
11. Pericardial Constriction (CT/CMR)
Diagnosis: Constrictive Pericarditis.
Pathognomonic Sign: Thickened pericardium (>4mm) and septal bounce on cine imaging.
Clinical Risk: Diastolic heart failure, venous congestion.
Management: Surgical pericardiectomy.
Cross-Examination (5 Q&A):
Q: What is the normal thickness of the pericardium? A: Less than 2mm.
Q: What CT finding strongly supports a chronic etiology? A: Dense pericardial calcification.
Q: What is the "conical RV" sign? A: Tubular deformity of the RV due to encasement.
Q: Differentiate from restrictive cardiomyopathy on CMR? A: Restrictive has normal pericardium and often abnormal myocardial LGE.
Q: Why is cine CMR important? A: It demonstrates ventricular interdependence (septal shift during respiration).
12. Aortic Aneurysm (Thoracic)
Diagnosis: Thoracic Aortic Aneurysm.
Pathognomonic Sign: Dilation of the thoracic aorta greater than 40mm.
Clinical Risk: Aortic dissection, rupture.
Management: Serial CT surveillance; surgical graft if criteria are met.
Cross-Examination (5 Q&A):
Q: At what size is surgery indicated for sporadic cases? A: 55mm.
Q: At what size is surgery indicated for Marfan syndrome? A: 50mm (or 45mm with family history of rupture).
Q: What is the "tulip bulb" sign? A: Characteristic root dilation seen in Marfan syndrome.
Q: Which dimension must be measured? A: True orthogonal cross-section, outer edge to outer edge.
Q: What is an intramural hematoma (IMH)? A: Hemorrhage into the aortic wall without a continuous intimal tear; a dissection variant.
13. Coarctation of the Aorta
Diagnosis: Aortic Coarctation.
Pathognomonic Sign: Focal narrowing of the aortic isthmus just distal to the left subclavian artery.
Clinical Risk: Secondary hypertension, heart failure.
Management: Transcatheter stenting or surgical repair.
Cross-Examination (5 Q&A):
Q: What collateral vessels dilate? A: Internal mammary arteries and intercostal arteries.
Q: What does collateral dilation cause on a chest X-ray? A: Rib notching (inferior border).
Q: What is pseudocoarctation? A: Kinking of the aorta without a significant PG or collateral formation.
Q: What cardiac anomaly is present in 50-80% of cases? A: Bicuspid aortic valve.
Q: Where exactly is the isthmus? A: Between the origin of the left subclavian artery and the ductus arteriosus.
14. Bicuspid Aortic Valve (CT)
Diagnosis: Bicuspid Aortic Valve.
Pathognomonic Sign: Two functioning aortic cusps, often with a visible fibrous raphe (fusion line) on systolic cross-section.
Clinical Risk: Early calcific aortic stenosis, aortopathy.
Management: Echo surveillance and aortic root measurements.
Cross-Examination (5 Q&A):
Q: What is the most common fusion pattern? A: Right-Left cusp fusion.
Q: What is a raphe? A: The ridge of tissue where the two cusps failed to separate.
Q: Does the presence of a raphe change the prognosis? A: Yes, raphes are associated with faster progression of stenosis.
Q: Why use CT instead of Echo? A: CT is superior for planning TAVR in BAV patients, assessing the calcium burden and root geometry.
Q: What is the Sievers classification? A: Categorizes BAV by the number of raphes (Type 0, 1, or 2).
15. Coronary Stent Patency (CCTA)
Diagnosis: In-Stent Restenosis vs Patent Stent.
Pathognomonic Sign: Continuous contrast density within the stent (patent) versus a dark filling defect inside the struts (restenosis).
Clinical Risk: Recurrent angina, stent thrombosis.
Management: Invasive angiography if restenosis is identified.
Cross-Examination (5 Q&A):
Q: Why are stents difficult to image on CT? A: The metallic struts cause blooming artifact that obscures the lumen.
Q: What stent size is generally required for accurate CT evaluation? A: Stents greater than 3.0mm in diameter.
Q: What reconstruction kernel is used? A: Sharp tissue kernels to minimize blooming.
Q: What is the difference between thrombosis and restenosis? A: Thrombosis is acute/dark; restenosis is neointimal hyperplasia (often lower density).
Q: Can you evaluate bioresorbable scaffolds with CT? A: Yes, they are radiolucent, making the lumen much easier to see than metallic stents.
16. Myocardial Viability (Nuclear / CMR)
Diagnosis: Hibernating Myocardium.
Pathognomonic Sign: CMR shows LGE less than 50% transmurality; PET shows mismatch (reduced perfusion but preserved FDG uptake).
Clinical Risk: Ischemic cardiomyopathy progressing to irreversible scar.
Management: Coronary revascularization (CABG or PCI).
Cross-Examination (5 Q&A):
Q: What is the "mismatch" pattern on PET? A: Decreased flow (Ammonia/Rubidium) but preserved metabolism (FDG).
Q: What does a "match" pattern mean? A: Both flow and metabolism are absent (irreversible scar).
Q: On CMR, what transmurality dictates viability? A: 1-25% is highly viable, 26-50% is indeterminate, >50% is non-viable.
Q: What is the 5-point grading scale for LGE? A: 0, 1-25, 26-50, 51-75, 76-100% transmurality.
Q: Is wall thickness important? A: Yes, an end-diastolic wall thickness less than 5.5mm usually indicates non-viable scar.
17. Intracardiac Tumor (CMR)
Diagnosis: Cardiac Mass (Tissue Characterization).
Pathognomonic Sign: First-pass perfusion and mapping differentiate vascular tumors from avascular thrombi.
Clinical Risk: Embolization, valvular obstruction.
Management: Surgical resection versus anticoagulation.
Cross-Examination (5 Q&A):
Q: How does a thrombus appear on first-pass perfusion? A: Completely avascular (dark) compared to the myocardium.
Q: How does a myxoma appear? A: Heterogeneous with patchy enhancement and a stalk attached to the IAS.
Q: What is the classic CMR sign of a lipoma? A: Bright on T1 mapping, and darkens entirely on fat-saturated sequences.
Q: Fibroma characteristic? A: Very intense Late Gadolinium Enhancement (highly fibrotic).
Q: Most common malignant primary tumor? A: Angiosarcoma, intensely vascular and enhancing.
18. RV Dysplasia (ARVC)
Diagnosis: Arrhythmogenic Right Ventricular Cardiomyopathy.
Pathognomonic Sign: RV wall thinning, aneurysms, regional akinesia, and fibrofatty infiltration (bright on T1).
Clinical Risk: Ventricular Tachycardia (LBBB morphology) and SCD.
Management: ICD placement and exercise restriction.
Cross-Examination (5 Q&A):
Q: What is the "triangle of dysplasia"? A: RV inflow, RV outflow, and RV apex.
Q: Why is CMR the gold standard? A: Superior visualization of the thin RV free wall and tissue characterization.
Q: Is fat infiltration alone diagnostic? A: No, it must be accompanied by regional wall motion abnormalities.
Q: What ECG finding correlates with this? A: Epsilon wave in leads V1-V3.
Q: What genetic mutation is responsible? A: Desmosomal protein mutations (e.g., Plakophilin-2).
19. SVC / IVC Anomalies
Diagnosis: Venous Return Anomaly.
Pathognomonic Sign: Duplication of the SVC, or azygos continuation of an interrupted IVC.
Clinical Risk: Usually asymptomatic, complicates EP studies or surgeries.
Management: Document in chart prior to any invasive right-heart procedure.
Cross-Examination (5 Q&A):
Q: What is the most common SVC anomaly? A: Persistent Left SVC draining into the coronary sinus.
Q: What happens in "azygos continuation of the IVC"? A: The hepatic segment of the IVC is absent; blood drains via the azygos vein to the SVC.
Q: What syndrome is highly associated with azygos continuation? A: Polysplenia (Left Isomerism).
Q: Does an interrupted IVC cause cyanosis? A: No, blood still reaches the right atrium.
Q: How does a Left SVC complicate pacemaker placement? A: The lead must navigate the acute angle from the coronary sinus into the RV.
20. Aberrant Right Subclavian Artery (ARSA)
Diagnosis: ARSA.
Pathognomonic Sign: The right subclavian artery arises as the last branch of the aortic arch and courses retroesophageally.
Clinical Risk: Dysphagia lusoria (trouble swallowing).
Management: Surgical division and reimplantation if severely symptomatic.
Cross-Examination (5 Q&A):
Q: What is the normal order of aortic arch branches? A: Brachiocephalic trunk, Left Common Carotid, Left Subclavian.
Q: What is the order in ARSA? A: Right Common Carotid, Left Common Carotid, Left Subclavian, ARSA.
Q: What is the "diverticulum of Kommerell"? A: An aneurysmal dilation at the origin of the aberrant artery.
Q: Where does the artery pass? A: Posterior to the esophagus (80%), between trachea and esophagus (15%), or anterior to trachea (5%).
Q: Does it form a complete vascular ring? A: No, it is an incomplete ring, but can still cause compression.
CARDIAC MRI (CMR) PATTERNS
21. Acute Myocarditis
Diagnosis: Acute Myocarditis.
Pathognomonic Sign: Epicardial or mid-wall Late Gadolinium Enhancement (LGE) with corresponding high T2 signal (edema).
Clinical Risk: Ventricular arrhythmias, acute heart failure, cardiogenic shock.
Management: Supportive care, GDMT for heart failure, avoid exercise for 3-6 months.
Cross-Examination (5 Q&A):
Q: What are the Lake Louise Criteria? A: CMR criteria requiring non-ischemic myocardial injury (LGE or high T1) and myocardial edema (high T2).
Q: Where is LGE classically located? A: Inferolateral wall, mid-wall or epicardial.
Q: How does it differ from MI on CMR? A: MI always involves the subendocardium in a vascular territory.
Q: What is the role of parametric mapping? A: Native T1 and T2 mapping quantify diffuse inflammation better than traditional dark-blood imaging.
Q: Most common viral etiology? A: Parvovirus B19, Coxsackievirus, or Adenovirus.
22. Cardiac Iron Overload
Diagnosis: Hemochromatosis / Transfusion Iron Overload.
Pathognomonic Sign: Markedly decreased myocardial T2* (T2 star) relaxation time.
Clinical Risk: Dilated cardiomyopathy, arrhythmias, heart failure.
Management: Iron chelation therapy (e.g., Deferoxamine).
Cross-Examination (5 Q&A):
Q: What T2* value indicates severe iron overload? A: Less than 10 milliseconds.
Q: What is the normal T2* value? A: Greater than 20 milliseconds.
Q: Does the liver or heart load iron first? A: Liver loads first; cardiac loading implies severe systemic disease.
Q: What happens to the CMR image overall? A: The myocardium becomes extremely dark (signal loss) on gradient-echo sequences.
Q: Is LGE typically present? A: No, unless there is secondary fibrosis from advanced heart failure.
23. Fabry Disease
Diagnosis: Anderson-Fabry Disease.
Pathognomonic Sign: Extremely low native T1 mapping values combined with massive left ventricular hypertrophy and inferolateral mid-wall LGE.
Clinical Risk: Severe HFpEF, malignant arrhythmias, renal failure.
Management: Enzyme Replacement Therapy (Agalsidase beta).
Cross-Examination (5 Q&A):
Q: What is the underlying pathophysiology? A: Lysosomal storage disorder with globotriaosylceramide accumulation.
Q: Why is native T1 low? A: Sphingolipid accumulation lowers the T1 relaxation time, unlike most cardiomyopathies which raise it.
Q: What is the classic LGE pattern? A: Basal inferolateral mid-wall scar.
Q: What does the ECG show? A: Short PR interval and severe LVH.
Q: Inheritance pattern? A: X-linked recessive.
24. Microvascular Obstruction (MVO)
Diagnosis: Acute Myocardial Infarction with MVO.
Pathognomonic Sign: A dark, hypoenhanced core within a bright area of subendocardial/transmural LGE.
Clinical Risk: Adverse remodeling, high risk of LV aneurysm, poor prognosis.
Management: Aggressive post-MI medical therapy; represents "no-reflow" phenomenon despite open epicardial artery.
Cross-Examination (5 Q&A):
Q: Why does the core remain dark? A: Contrast cannot enter the infarcted core due to destroyed capillary beds.
Q: Does MVO persist forever? A: No, it is usually replaced by dense scar tissue over weeks to months.
Q: When is MVO best visualized? A: On early gadolinium enhancement (1-3 minutes) or LGE (10-15 minutes).
Q: What happens to LV function if MVO is present? A: Poorer recovery of regional wall motion compared to MI without MVO.
Q: Cath lab equivalent? A: TIMI 0-1 flow or myocardial blush grade 0 after stenting.
25. Intramyocardial Hemorrhage (IMH)
Diagnosis: Hemorrhagic Myocardial Infarction.
Pathognomonic Sign: A very dark core on T2* or T2-weighted imaging within the infarcted territory.
Clinical Risk: Extreme risk for myocardial rupture and malignant remodeling.
Management: Strict blood pressure control, heart failure monitoring.
Cross-Examination (5 Q&A):
Q: How does IMH differ from MVO? A: MVO is lack of perfusion (dark on LGE); IMH is actual bleeding (dark on T2* due to iron from hemoglobin).
Q: Do they occur together? A: Yes, IMH almost always occurs within a zone of MVO.
Q: What causes it? A: Severe ischemia-reperfusion injury disrupting the vascular endothelium.
Q: When does it appear? A: Typically within the first few days after acute reperfusion.
Q: What is the long-term CMR consequence? A: Residual iron deposition in the scar tissue.
26. Apical Hypertrophic Cardiomyopathy
Diagnosis: Apical HCM (Yamaguchi Syndrome).
Pathognomonic Sign: "Spade-like" configuration of the LV cavity in end-diastole on 4-chamber cine, with apical LGE.
Clinical Risk: Apical aneurysm formation, apical thrombus, VT.
Management: Beta-blockers, anticoagulation if aneurysm/thrombus forms.
Cross-Examination (5 Q&A):
Q: What is the classic ECG finding? A: Giant negative T-waves (>10mm) in precordial leads.
Q: Is there LVOT obstruction? A: No, obstruction is mid-cavitary if present.
Q: Why is CMR superior to Echo here? A: Echo often misses the apex due to near-field artifact and foreshortening.
Q: What is an apical pouch? A: A thin-walled apical aneurysm that forms due to high apical pressures.
Q: Ethnicity association? A: More common in Asian populations.
27. Non-Ischemic Dilated Cardiomyopathy (NIDCM)
Diagnosis: NIDCM.
Pathognomonic Sign: Dilated, hypokinetic LV with mid-wall longitudinal striae of LGE (typically in the septum).
Clinical Risk: Progressive pump failure, bundle branch blocks, VT.
Management: GDMT, CRT-D if QRS >150ms and EF <35%.
Cross-Examination (5 Q&A):
Q: What does mid-wall LGE indicate? A: Myocardial fibrosis, an independent predictor of sudden cardiac death.
Q: How common is LGE in NIDCM? A: Present in about 30-40% of cases.
Q: How do you definitively rule out ischemic CM? A: Absence of subendocardial LGE and normal coronary arteries.
Q: What happens to T1 mapping? A: Extracellular volume (ECV) is diffusely increased due to interstitial fibrosis.
Q: Reversibility? A: Some cases (e.g., tachycardia-induced or alcohol-induced) may reverse with treatment.
28. Endomyocardial Fibrosis (Loeffler's)
Diagnosis: Hypereosinophilic Syndrome (Loeffler Endocarditis).
Pathognomonic Sign: Diffuse subendocardial LGE with apical obliteration by thrombus/fibrosis.
Clinical Risk: Severe restrictive cardiomyopathy, systemic thromboembolism.
Management: Corticosteroids, anticoagulation, heart failure therapy.
Cross-Examination (5 Q&A):
Q: What lab abnormality is universally present in the acute phase? A: Peripheral blood eosinophilia.
Q: What is the "V-sign"? A: The typical V-shaped apical obliteration seen on 4-chamber CMR.
Q: Differentiate from apical HCM? A: HCM is thickened muscle; Loeffler's is thickened fibrotic endocardium with thrombus.
Q: Are both ventricles involved? A: Often biventricular involvement.
Q: What happens to the AV valves? A: Tethering leads to severe MR and TR.
29. Chagas Cardiomyopathy
Diagnosis: Chagas Disease.
Pathognomonic Sign: Apical aneurysm with delayed enhancement, but completely normal coronary arteries.
Clinical Risk: High risk of apical thrombus, intractable VT, progressive HF.
Management: Amiodarone for arrhythmias, anticoagulation, heart failure therapy.
Cross-Examination (5 Q&A):
Q: Endemic region? A: Latin America (Trypanosoma cruzi).
Q: What is the typical LGE pattern? A: Inferolateral and apical, can be transmural or mid-wall.
Q: Does the aneurysm have a wide or narrow neck? A: Wide neck, true aneurysm.
Q: Classic ECG findings? A: RBBB and Left Anterior Fascicular Block (LAFB).
Q: Pathophysiology? A: Chronic parasite-induced immune-mediated myocardial destruction.
30. Arrhythmogenic Left Ventricular Cardiomyopathy (ALVC)
Diagnosis: ALVC.
Pathognomonic Sign: Ring-like subepicardial or mid-wall LGE involving the left ventricle, often with preserved LV function initially.
Clinical Risk: High incidence of Sudden Cardiac Death.
Management: ICD implantation, strict exercise avoidance.
Cross-Examination (5 Q&A):
Q: Genetic mutation commonly associated? A: Desmoplakin (DSP) or Filamin C (FLNC).
Q: How does it differ from ARVC? A: Predominant LV involvement; RV may be normal.
Q: Why is CMR essential? A: Echo is often completely normal in the early stages; only CMR shows the epicardial scar.
Q: What is the primary clinical presentation? A: VT with a RBBB morphology (originating from LV).
Q: Is fat infiltration seen? A: Yes, but fibro-fatty replacement is harder to see in the LV than the thin RV.
31. Adenosine Stress Perfusion Ischemia
Diagnosis: Inducible Myocardial Ischemia.
Pathognomonic Sign: A dark, subendocardial perfusion defect during peak vasodilator stress that is not present at rest, with no matching LGE.
Clinical Risk: Hemodynamically significant CAD.
Management: Coronary angiography and revascularization.
Cross-Examination (5 Q&A):
Q: How does Adenosine work? A: A2A receptor agonist causing microvascular dilation; diseased vessels cannot dilate, creating a flow mismatch.
Q: Why must it be subendocardial? A: The subendocardium is most vulnerable to ischemia; epicardial-only defects are usually artifacts.
Q: What is the "dark rim artifact"? A: A false perfusion defect at the blood-myocardium border due to Gibbs ringing.
Q: What is the antidote for adenosine? A: Aminophylline.
Q: Contraindications to adenosine? A: Severe asthma, 2nd/3rd degree heart block.
32. Phase-Contrast Flow (Qp:Qs)
Diagnosis: Clinically significant Left-to-Right Shunt (e.g., ASD, VSD).
Pathognomonic Sign: Phase-contrast mapping demonstrates a Pulmonary (Qp) to Systemic (Qs) flow ratio > 1.5.
Clinical Risk: Right heart volume overload, eventual pulmonary hypertension.
Management: Transcatheter or surgical closure of the defect.
Cross-Examination (5 Q&A):
Q: Where are the flows measured? A: Cross-sections of the Main Pulmonary Artery and the Ascending Aorta.
Q: What does a Qp:Qs of 1.0 mean? A: Normal physiology, no net shunting.
Q: What does a Qp:Qs < 1.0 mean? A: Right-to-Left shunt (e.g., Tetralogy of Fallot, Eisenmenger).
Q: Can phase contrast quantify valvular regurgitation? A: Yes, by measuring forward flow vs reverse flow (regurgitant fraction).
Q: What causes baseline phase offset errors? A: Eddy currents in the MRI scanner.
33. Ebstein Anomaly (CMR)
Diagnosis: Ebstein Anomaly.
Pathognomonic Sign: Apical displacement of the septal tricuspid leaflet (>8mm/m2) with accurate volumetry of the functional RV vs atrialized RV.
Clinical Risk: RV failure, WPW syndrome, TR.
Management: Surgical repair (Cone procedure) if symptomatic or severe RV dilation.
Cross-Examination (5 Q&A):
Q: Why use CMR over Echo for Ebstein? A: CMR is the gold standard for accurate RV volumes and Ejection Fraction.
Q: What constitutes the "atrialized" RV? A: The myocardium between the anatomic tricuspid annulus and the displaced leaflets.
Q: What is the functional RV? A: The trabecular and outflow portions distal to the displaced leaflets.
Q: Does the RV usually have LGE? A: Rarely, but severe cases may show fibrosis.
Q: Common associated anomaly? A: ASD or PFO (found in >50% of cases).
34. Takotsubo Cardiomyopathy (CMR)
Diagnosis: Stress Cardiomyopathy.
Pathognomonic Sign: Apical ballooning with marked myocardial edema (high T2) but ABSENCE of any Late Gadolinium Enhancement.
Clinical Risk: Acute heart failure, cardiogenic shock, LV thrombus, dynamic LVOT obstruction.
Management: Supportive care; typically resolves completely in 4-8 weeks.
Cross-Examination (5 Q&A):
Q: What is the key discriminator from acute anterior MI? A: Complete absence of LGE in Takotsubo.
Q: What causes the high T2 signal? A: Severe, transient myocardial edema.
Q: Which segments are hyperkinetic? A: Basal segments.
Q: Are there other variants? A: Yes, mid-ventricular, basal (reverse Takotsubo), and focal.
Q: Trigger? A: Intense physical or emotional catecholamine surge.
35. Cardiac Lipoma
Diagnosis: Benign Cardiac Lipoma.
Pathognomonic Sign: An encapsulated mass that is uniformly bright on T1-weighted images and becomes completely dark on fat-saturated sequences.
Clinical Risk: Arrhythmias or obstruction if extremely large.
Management: Usually conservative observation; surgery if symptomatic.
Cross-Examination (5 Q&A):
Q: Most common locations? A: RA, LV, or epicardial space.
Q: Differentiate from Lipomatous Hypertrophy of the IAS? A: Lipoma is encapsulated and can be anywhere; LH-IAS is unencapsulated, restricted to the septum, and spares the fossa ovalis.
Q: Does a lipoma enhance with Gadolinium? A: No, it is avascular.
Q: Density on CT? A: Highly negative Hounsfield Units (-50 to -100 HU).
Q: Malignant counterpart? A: Liposarcoma (heterogeneous, invasive, enhances).
CT ANGIOGRAPHY (CCTA) PATTERNS
36. Myocardial Bridging
Diagnosis: Myocardial Bridge.
Pathognomonic Sign: An epicardial coronary artery (usually the LAD) dips into the myocardium and is surrounded by muscle.
Clinical Risk: Systolic vessel compression leading to angina or rare arrhythmias.
Management: Beta-blockers to increase diastolic filling time; avoid nitrates.
Cross-Examination (5 Q&A):
Q: Which vessel is most commonly involved? A: The mid-Left Anterior Descending (LAD) artery.
Q: Why do nitrates worsen symptoms? A: They increase reflex tachycardia and contractility, worsening systolic compression.
Q: What is the "step-down, step-up" sign? A: The angiographic appearance of the vessel diving into and out of the muscle.
Q: Are plaques common inside the bridged segment? A: No, the bridged segment is protected from atherosclerosis; plaques form proximal to the bridge.
Q: Surgical option? A: Supra-arterial myotomy (unroofing).
37. TAVR Annular Assessment
Diagnosis: Severe AS (Pre-TAVR Planning).
Pathognomonic Sign: 3D reconstruction showing an elliptical aortic annulus with quantification of perimeter, area, and calcification.
Clinical Risk: Annular rupture, paravalvular leak, coronary occlusion if sizing is incorrect.
Management: Select appropriately sized transcatheter valve based on area/perimeter derived from CT.
Cross-Examination (5 Q&A):
Q: Why use systolic phase CT for the annulus? A: The annulus is largest in systole; using diastole leads to undersizing and paravalvular leak.
Q: How is the basal ring (annulus) defined? A: A virtual ring formed by joining the three lowest points (nadir) of the aortic cusps.
Q: What is a critical measurement to prevent coronary occlusion? A: Coronary ostial height (must typically be >10-12mm).
Q: What is the Sinus of Valsalva width requirement? A: Must be wide enough to accommodate the displaced native leaflets (typically >30mm).
Q: How does calcium distribution affect TAVR? A: Heavy, asymmetric LVOT calcium increases the risk of annular rupture and heart block.
38. HALT (Hypoattenuated Leaflet Thickening)
Diagnosis: Subclinical Prosthetic Valve Thrombosis.
Pathognomonic Sign: Meniscus-shaped, low-attenuation thickening on the aortic side of the bioprosthetic leaflets on 4D CT.
Clinical Risk: Premature valve degeneration, TIA/Stroke, increasing transvalvular gradients.
Management: Oral anticoagulation (NOAC or Warfarin).
Cross-Examination (5 Q&A):
Q: Is the patient usually symptomatic? A: No, HALT is usually subclinical.
Q: What does HALT restrict? A: It causes Reduced Leaflet Motion (RELM).
Q: Does DAPT clear HALT? A: No, Dual Antiplatelet Therapy is ineffective; it requires full anticoagulation.
Q: When is it typically discovered? A: On routine post-TAVR CT at 30 days or 1 year.
Q: Can it happen in surgical valves? A: Yes, but it is more frequently recognized in transcatheter valves.
39. Left Atrial Appendage Thrombus
Diagnosis: LAA Thrombus.
Pathognomonic Sign: A persistent filling defect in the LAA on both early arterial and 1-minute delayed venous phase CT.
Clinical Risk: Systemic embolism (Stroke).
Management: Anticoagulation; contraindicates cardioversion or AFib ablation.
Cross-Examination (5 Q&A):
Q: Why is delayed imaging mandatory? A: To differentiate true thrombus from sluggish flow (severe spontaneous echo contrast/sludge).
Q: How does sluggish flow behave on delayed imaging? A: It fills in with contrast (becomes bright).
Q: What Hounsfield Unit confirms a thrombus? A: Usually less than 50 HU on delayed imaging.
Q: Which LAA morphology has the highest risk for thrombus? A: "Cauliflower" shape.
Q: Alternative imaging if CT is contraindicated? A: Transesophageal Echocardiogram (TEE).
40. Pulmonary Vein Variant Anatomy
Diagnosis: Pre-AFib Ablation Anatomy.
Pathognomonic Sign: Identification of common trunks or accessory pulmonary veins (e.g., right middle PV).
Clinical Risk: Incomplete isolation during AFib ablation if anatomy is unrecognized.
Management: Use 3D CT map overlaid on electro-anatomical mapping system during procedure.
Cross-Examination (5 Q&A):
Q: What is most common PV variant? A: Left common ostium (short common trunk for left upper and lower veins).
Q: What is a right middle pulmonary vein? A: An accessory vein draining the right middle lobe directly into the LA.
Q: Why is CT done prior to AFib ablation? A: To define anatomy, measure ostial sizes, and rule out LAA thrombus.
Q: Complication of ablating too deep inside the vein? A: Pulmonary vein stenosis.
Q: What structure is evaluated behind the LA to prevent fistulas? A: The esophagus.
41. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Diagnosis: CTEPH.
Pathognomonic Sign: Eccentric, calcified, mural thrombus in the pulmonary arteries, with webs, bands, and mosaic lung attenuation.
Clinical Risk: Progressive right heart failure, cor pulmonale.
Management: Pulmonary thromboendarterectomy (PTE) or balloon pulmonary angioplasty (BPA).
Cross-Examination (5 Q&A):
Q: How does CTEPH clot differ from acute PE on CT? A: Acute is central and distends the vessel; CTEPH is eccentric and retracts the vessel.
Q: What is mosaic attenuation? A: Patchy areas of dark (oligemic) and bright (hyperemic) lung parenchyma.
Q: What causes the webs and bands? A: Organized, recanalized chronic thrombus.
Q: What is the definitive cure? A: Surgical PTE, if lesions are surgically accessible (proximal).
Q: Required hemodynamics for diagnosis? A: Mean PA pressure > 20 mmHg and PAWP < 15 mmHg after 3 months of anticoagulation.
42. Aortic Intramural Hematoma (IMH)
Diagnosis: IMH (Acute Aortic Syndrome).
Pathognomonic Sign: Crescent-shaped, high-attenuation (bright) thickening of the aortic wall on NON-contrast CT.
Clinical Risk: Progression to overt aortic dissection or rupture.
Management: Same as dissection (Type A = surgery, Type B = medical).
Cross-Examination (5 Q&A):
Q: Why is a non-contrast CT essential? A: Contrast in the lumen will obscure the high-attenuation blood in the wall.
Q: Is there an intimal flap? A: No, the intima is intact; bleeding occurs within the media via vasa vasorum rupture.
Q: Does it enhance with contrast? A: No, it remains dark on contrast phases.
Q: What is an ulcer-like projection (ULP)? A: A focal contrast-filled outpouching indicating a localized intimal tear; high risk of progression.
Q: What is the typical patient profile? A: Elderly, severe hypertension.
43. Penetrating Atherosclerotic Ulcer (PAU)
Diagnosis: PAU.
Pathognomonic Sign: Focal contrast-filled outpouching extending through the calcified intima into the aortic media.
Clinical Risk: Saccular aneurysm formation, IMH, or transmural rupture.
Management: TEVAR (Thoracic Endovascular Aortic Repair) if symptomatic or rapidly expanding.
Cross-Examination (5 Q&A):
Q: Where do PAUs most commonly occur? A: In the descending thoracic aorta (where atherosclerosis is worst).
Q: What accompanies almost all PAUs? A: Extensive, severe atherosclerosis and calcification.
Q: Can a PAU cause an IMH? A: Yes, blood can dissect from the ulcer into the media.
Q: How does it differ from a true aneurysm? A: PAU is a focal defect in the wall; true aneurysm involves dilation of all three layers.
Q: Primary symptom? A: Focal back pain or chest pain.
44. Anomalous Left Coronary Artery from Pulmonary Artery (ALCAPA)
Diagnosis: ALCAPA (Bland-White-Garland Syndrome).
Pathognomonic Sign: The LMCA originates from the main pulmonary artery instead of the aorta.
Clinical Risk: Severe myocardial ischemia, LV dysfunction, sudden infant death.
Management: Surgical reimplantation into the aorta.
Cross-Examination (5 Q&A):
Q: Why does ischemia occur? A: As PVR falls after birth, deoxygenated blood flows retrograde from the LCA into the PA (steal phenomenon).
Q: What happens to the RCA? A: It becomes massively dilated & tortuous to provide collaterals to the left system.
Q: Typical presentation age? A: 1-2 months of age (when PVR drops).
Q: What do you see on Echo color Doppler? A: Reverse flow in the LCA entering the pulmonary trunk.
Q: Subendocardial LGE on CMR? A: Present in the anterolateral walls due to chronic infarction.
45. Pericardial Cyst
Diagnosis: Pericardial Cyst.
Pathognomonic Sign: A well-circumscribed, thin-walled, water-density (0-20 HU) mass, typically at the right cardiophrenic angle.
Clinical Risk: Mostly benign; rarely causes compression or ruptures.
Management: Observation unless symptomatic.
Cross-Examination (5 Q&A):
Q: Does it enhance with contrast? A: No, it is entirely fluid-filled and avascular.
Q: Most common location? A: Right anterior cardiophrenic angle (70%).
Q: CMR appearance? A: Bright on T2 (fluid) and dark on T1.
Q: Differentiate from a solid tumor? A: Solid tumors have soft-tissue attenuation (>30 HU) and enhance.
Q: Embryological origin? A: Failure of fusion of mesenchymal lacunae that form the pericardial sac.
46. Pulmonary Arteriovenous Malformation (PAVM)
Diagnosis: PAVM.
Pathognomonic Sign: A tangled nidus of vessels connecting a dilated feeding PA directly to a draining PV
Clinical Risk: Right-to-left shunt leading to hypoxemia, paradoxical stroke, or brain abscess.
Management: Transcatheter coil or plug embolization.
Cross-Examination (5 Q&A):
Q: Associated genetic syndrome? A: Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu).
Q: Why do brain abscesses occur? A: Loss of the pulmonary capillary bed's filtering function allows bacteria to reach the brain.
Q: What is the classic clinical triad? A: Cyanosis, clubbing, and polycythemia.
Q: Echo finding? A: Positive agitated saline contrast study (bubbles appear in LA after 3-5 cardiac cycles).
Q: Should all PAVMs be treated? A: Yes, if the feeding artery is > 3mm in diameter.
47. Aortic Pseudoaneurysm
Diagnosis: Pseudoaneurysm (False Aneurysm).
Pathognomonic Sign: Contrast-filled outpouching outside the normal aortic contour, connected by a narrow neck.
Clinical Risk: Extremely high risk of spontaneous rupture.
Management: Urgent surgical or endovascular repair.
Cross-Examination (5 Q&A):
Q: What layers are involved? A: None; it is contained only by adventitia or surrounding mediastinal tissue.
Q: Most common causes? A: Post-surgical (at anastomosis sites), trauma, or infection (mycotic).
Q: Why is the neck narrow? A: Because it originates from a focal tear in the vessel wall.
Q: Color Doppler finding on Echo? A: "Yin-yang" sign of swirling blood flow.
Q: Difference from true aneurysm? A: True aneurysm has all three layers (intima, media, adventitia) intact.
48. Kawasaki Giant Coronary Aneurysm (CT)
Diagnosis: Kawasaki Disease.
Pathognomonic Sign: Massive, often heavily calcified, saccular dilations of the proximal coronary arteries (>8mm).
Clinical Risk: Intracoronary thrombosis and myocardial infarction.
Management: Long-term systemic anticoagulation; CABG if severely stenotic distally.
Cross-Examination (5 Q&A):
Q: Why use CCTA in adults with Kawasaki? A: To map the extent of aneurysms, calcification, and hidden stenoses prior to CABG.
Q: Where do stenoses usually occur? A: At the proximal and distal ends of the aneurysm.
Q: Why do they calcify? A: Chronic inflammation and healing of the arteritis.
Q: Are distal vessels involved? A: Usually spares the distal vessels, making CABG feasible.
Q: What is the primary cause of ischemia? A: Sluggish flow in the aneurysm causing thrombus, or severe calcific stenosis at the outlet.
49. Partial Anomalous Pulmonary Venous Return (PAPVR)
Diagnosis: PAPVR.
Pathognomonic Sign: One or more (but not all) pulmonary veins drain into the systemic venous circulation (SVC, IVC, or RA).
Clinical Risk: Right heart volume overload and PHTN (acts like an ASD).
Management: Surgical baffle if Qp:Qs > 1.5.
Cross-Examination (5 Q&A):
Q: Most common variant? A: Right upper pulmonary vein draining into the Superior Vena Cava.
Q: What defect is almost always associated with the SVC variant? A: Sinus Venosus ASD.
Q: Scimitar syndrome involves which vein? A: Right pulmonary vein draining into the IVC.
Q: Does PAPVR cause cyanosis? A: No, it is a Left-to-Right shunt.
Q: Why is CCTA the gold standard? A: Excellent 3D spatial resolution maps the exact venous course for the surgeon.
50. Sinus Venosus ASD (CT/CMR)
Diagnosis: Sinus Venosus ASD.
Pathognomonic Sign: A defect in the superior atrial septum immediately adjacent to the SVC/RA junction.
Clinical Risk: Right ventricular dilation, atrial arrhythmias, PHTN.
Management: Surgical patch closure.
Cross-Examination (5 Q&A):
Q: Why is Echo often insufficient? A: The defect is high and posterior, easily missed on TTE (requires TEE, CT,or CMR).
Q: What must always be looked for on the scan? A: Anomalous pulmonary veins (PAPVR).
Q: Can this defect close spontaneously? A: No.
Q: Can it be closed with a transcatheter device? A: Traditionally no, due to lack of a superior rim and anomalous veins, though complex covered stents are being trialed.
Q: What defines a "Warden procedure"? A: Surgically re-routing the SVC to the right atrial appendage while baffling the anomalous veins to the LA.
Comments
Post a Comment
Join the academic discussion. Share your clinical insights, questions, or perspectives below.